Verisante to launch new research product this week
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is launching a new product at the SPIE Photonics West 2014 industry exhibit in San Francisco, Calif. this week. The company will be introducing and...
View ArticleVerisante gains additional media exposure
Verisante Technology (TSX-V:VRS; OTCQX:VRSEF) is to be featured on CEO Clips on The Documentary Channel, with CEO Thomas Braun discussing the company’s ground-breaking systems for the early detection...
View ArticleVerisante expands its sales and marketing team
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has hired Jason Mangler as director of sales to guide the company’s worldwide sales and marketing strategy and also hired Kim Ellis as its sales...
View ArticleVerisante recognizes skin cancer awareness month
May is skin cancer awareness month and Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is reminding the public to wear sunscreen and get screened for skin cancer. Skin cancer is the most common form of...
View ArticleVerisante completes Core prototype
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has completed the development of the Core series commercial prototype to aid in the detection of lung cancer. The Core system, which is based on the same...
View ArticleVerisante receives F&S technology innovation award
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has received the Frost & Sullivan 2014 North American Technology Innovation Leadership of the Year Award for In Vivo Cancer Detection for its skin...
View ArticleVerisante displays Aura at BC Cancer Foundation
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is partnering with the BC Cancer Foundation to showcase Verisante Aura, a device for the rapid detection of skin cancer. Aura “We are very appreciative of...
View ArticleVerisante adds Drs. Beer and Werschler to its CAB
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Kenneth Beer and Dr. Wm. Philip Werschler to the company’s clinical advisory board. “Both Dr. Beer and Dr. Werschler have extensive...
View ArticleVerisante appoints Dr. Branko Palcic to its board
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Branko Palcic to its board, effective immediately, replacing Joe Biegel, who has resigned. In a statement, president and CEO, Thomas...
View ArticleVerisante begins FDA approval process for Aura
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has initiated communications with the FDA for the approval of Aura, a device for the detection of skin cancer. “Verisante has now submitted documents to...
View ArticleVerisante to seek FDA approval of Aura skin cancer device
In addition to ramping up distribution of its Aura non-invasive skin cancer detection device this year, Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is preparing the process to seek FDA approval of...
View ArticleAnalysts start AURA Biosciences at OP, buy
Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on...
View Article